Your browser doesn't support javascript.
loading
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan, Brian G; Rubin, David T; Danese, Silvio; Vermeire, Severine; Abhyankar, Brihad; Sankoh, Serap; James, Alexandra; Smyth, Michael.
Afiliación
  • Feagan BG; Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada. Electronic address: bfeagan@robarts.ca.
  • Rubin DT; University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois.
  • Danese S; Istituto Clinico Humanitas, Milan, Italy.
  • Vermeire S; University Hospital Gasthuisberg, Leuven, Belgium.
  • Abhyankar B; Takeda Development Centre Europe Ltd, London, United Kingdom.
  • Sankoh S; Takeda Pharmaceuticals International Co, Cambridge, Massachusetts.
  • James A; Takeda Development Centre Europe Ltd, London, United Kingdom.
  • Smyth M; Takeda Development Centre Europe Ltd, London, United Kingdom.
Clin Gastroenterol Hepatol ; 15(2): 229-239.e5, 2017 02.
Article en En | MEDLINE | ID: mdl-27639327

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Colitis Ulcerosa / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Colitis Ulcerosa / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2017 Tipo del documento: Article
...